Companies › Nuvation Bio
3 active drug programs in 7 registered trials: 3 Phase 3, 3 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Taletrectinib Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor | ROS1, NTRK1, NTRK2, NTRK3 | Phase 3 | Non Small Cell Lung Cancer; Non-small Cell Lung Cancer (NSCLC) | Jun 2027 |
| Safusidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 3 | Glioma; Grade 2 IDH1-mutant Glioma | Dec 2028 |
| NUV-1511 | – | Phase 1 | Advanced Solid Tumor | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06334432 | NUV-1511 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2027 |
| NCT04395677 | Taletrectinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT04919811 | Taletrectinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT05303519 | Safusidenib | Phase 3 | Glioma | Oncology | Dec 2028 |
| NCT06564324 | Taletrectinib | Phase 3 | Non Small Cell Lung Cancer | Oncology | Jan 2029 |
| NCT07154706 | Taletrectinib | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Aug 2030 |
| NCT07703436 | Safusidenib | Phase 2 | Grade 2 IDH1-mutant Glioma | Oncology | Sep 2030 |
Cash and short-term investments of $663m on 2026-09-30; operating cash outflow about $103m a year; runway about 78 months at that burn, to Mar 2033; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Bristol-Myers Squibb Xuanzhu Biopharmaceutical Roche Turning Point Therapeutics Dompé Farmaceutici Teligene US Bayer Servier IDEAYA Biosciences Ascentage Pharma Group
Xuanzhu Biopharmaceutical Hutchmed Servier Corvus Pharmaceuticals Avistone Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.